REGN Overview
Upcoming Projects (REGN)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (REGN)
-
Discussing the 52 week results of the Barzolvolimab Phase 2 study in CSU (Chronic Spontaneous Urticaria) at EADV 2024
Tickers: CLDX, JSPR, REGN, NVS
Executed On: Oct 09, 2024 at 12:00 PM EDT -
A Second Look: Discussing current uptake for Regeneron's Eylea (aflibercept) HD uptake and Roche Vabysmo
Tickers: REGN, RHHBY
Executed On: Sep 09, 2024 at 02:30 PM EDT -
Discussing current uptake for Regeneron's Eylea (aflibercept) HD uptake and Roche Vabysmo
Tickers: REGN, RHHBY
Executed On: Aug 29, 2024 at 04:30 PM EDT -
Discussing the potential of Roche's Susvimo, a surgical ocular implant designed to slowly release ranibizumab for the treatment of Wet-AMD.
Tickers: RHHBY, REGN, OCUL, EYPT
Executed On: Jul 18, 2024 at 03:00 PM EDT -
A second look: Discussing Regeneron's Eylea (aflibercept) HD uptake and trends following the April 1 J-Code
Tickers: REGN, RHHBY
Executed On: Jul 12, 2024 at 02:00 PM EDT -
Discussing Regeneron's Eylea (aflibercept) HD uptake and trends following the April 1 J-Code
Tickers: REGN, RHHBY
Executed On: Jul 11, 2024 at 04:30 PM EDT -
Discussing the current treatment landscape for retinal diseases with a prescriber of Eylea and Vabysmo.
Tickers: REGN, RHHBY
Executed On: May 16, 2024 at 10:15 AM EDT -
Advancing Multiple Myeloma Treatment: Insights into Regeneron's Linvoseltamab in the Phase I/II LINKER-MM1 Study presented at ASH 2023
Ticker: REGN
Executed On: Dec 18, 2023 at 10:00 AM EST -
Discussing the potential of Regeneron's otoferlin gene therapy, currently being investigated in the Phase 1/2 CHORD trial for patients with genetic hearing loss
Tickers: REGN, AKUS, LLY
Executed On: Dec 13, 2023 at 01:00 PM EST -
Discussing Novel Therapies in Dermatology with a focus on TYK2 in Psoriasis, IL-13 & OX-40(L) in Atopic Dermatitis and IL-17 in Hidradenitis Suppurativa
Tickers: REGN, BMY, AMGN
Executed On: Oct 18, 2023 at 12:30 PM EDT -
Discussing Regeneron & Sanofi's newly approved Kevzara® (sarilumab) in treating Polymyalgia Rheumatica (PMR)
Tickers: REGN, SNY
Executed On: Aug 31, 2023 at 09:00 AM EDT -
Discussing what's next for Regeneron's high dose Eylea post CRL, current trend of Vabysmo, biosimilars and reimbursement.
Tickers: REGN, RHHBY
Executed On: Jul 10, 2023 at 05:00 PM EDT -
A discussion of Replimune cemiplimab and the potential of RP1 in combination as a treatment for Cutaneous squamous cell carcinoma (cSCC)
Tickers: REPL, REGN
Executed On: Feb 15, 2023 at 04:30 PM EST -
Comparing EyePoint's EYP-1901 and 4D Molecular Therapeutics' gene therapy, 4D-150 for the treatment of wet-AMD
Tickers: EYPT, REGN, FDMT
Executed On: Feb 06, 2023 at 05:00 PM EST -
Digging into the Phase 1 data for REGN's LAG3 + Libtayo combination in frontline Melanoma
Tickers: REGN, BMY
Executed On: Oct 21, 2022 at 02:00 PM EDT -
Evaluating the potential of the new, higher dose version of Eylea in treating Macular Edema
Tickers: REGN, RHHBF
Executed On: Sep 29, 2022 at 03:00 PM EDT -
Digging into EyePoint Pharma's recent phase 1 data on its anti-VEGF candidate, EYP-1901 in macular edema and wet-AMD
Tickers: EYPT, REGN
Executed On: Sep 07, 2022 at 05:00 PM EDT -
A Second View: Reviewing the current treatment landscape for macular edema, with a focused look at Kodiak Sciences recent phase 3 data on Tarcocimab
Tickers: KOD, REGN
Executed On: Sep 02, 2022 at 10:00 AM EDT -
Reviewing the current treatment landscape for macular edema, with a focused look at Kodiak Sciences recent phase 3 data on Tarcocimab
Tickers: KOD, REGN
Executed On: Aug 29, 2022 at 10:30 AM EDT -
A look at Dupixent's recent FDA approval for its new indication of EoE and the Phase 3 study(NCT03633617)
Ticker: REGN
Executed On: Jun 22, 2022 at 03:00 PM EDT -
Discussing the potential of RP1 in combination with Libtayo in patients with Cutaneous squamous cell carcinoma (CSCC)
Tickers: REPL, REGN
Executed On: Mar 09, 2022 at 04:00 PM EST
Expired Projects (REGN)
-
Discussing the potential of Sanofi/Regeneron FDA approved therapy, Kevzara (sarilumab), in Polymyalgia rheumatica (PMR)
Tickers: SNY, REGN
Execute By: May 31, 2023 -
A third opinion: Does Squalamine stand a good chance of success in the current Phase 3 Wet AMD trial?
Tickers: OHRP, REGN, NVS, Ophthotech
Execute By: Jun 03, 2016
Upcoming & Overdue Catalysts (REGN)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (REGN)
-
PDUFA date for Dupixent (dupilumab) in Nasal polyps under priority review June 26, 2019
Tickers: REGN, SNY
Occurred on: Jun 26, 2019 -
PDUFA date for Regeneron's (REGN) Praluent (alirocumab) (ODYSSEY OUTCOMES study) for Cardiovascular events due April 28, 2019.
Ticker: REGN
Occurred on: Apr 26, 2019 -
DUPIXENT (dupilumab) for Moderate-to-Severe Asthma PDUFA date set for October 20, 2018
Ticker: REGN
Occurred on: Oct 19, 2018 -
Phase 3 Results for Dupixent (dupilumab) in Adolescents with Moderate-to-Severe Atopic Dermatitis Presented at the 27th EADV Congress
Tickers: REGN, SNY
Occurred on: Sep 15, 2018 -
Results in Regeneron's (REGN) Phase 3 Non Proliferative Diabetic Retinopathy Trial of EYLEA (aflibercept) Injection
Ticker: REGN
Occurred on: Mar 19, 2018 -
Regeneron Pharmaceuticals (REGN) to submit to FDA for DUPIXENT (dupilumab) in treating asthma
Ticker: REGN
Occurred on: Mar 02, 2018 -
Regeneron Pharmaceuticals (REGN) Phase 2 PD-1 antibody trial in non-small cell lung cancer set to begin in 2017
Ticker: REGN
Occurred on: Dec 13, 2017 -
Regeneron Pharmaceuticals (REGN) trial on DUPIXENT (dupilumab) in food allergy set to begin in second half of 2017
Ticker: REGN
Occurred on: Oct 16, 2017 -
Phase 2 Study Results for Regeneron's(REGN) Dupilumab in Patients With Active Moderate-to-Severe Eosinophilic Esophagitis Released
Tickers: REGN, SNY
Occurred on: Oct 16, 2017 -
Regeneron Pharmaceuticals (REGN) Phase 2 PD-1 antibody trial in basal cell carcimonia set to begin in 2017
Ticker: REGN
Occurred on: Aug 03, 2017 -
Regeneron (REGN) and Sanofi (SNY) rheumatoid arthritis drug Kevzara (sarilumab) granted FDA approval
Tickers: REGN, SNY
Occurred on: May 22, 2017 -
Sarilumab BLA submission expected first quarter of 2017
Ticker: REGN
Occurred on: Apr 28, 2017 -
PDUFA Date of March 29, 2017 Set for Regeneron (REGN) and Sanofi's (SNY) Dupilumab in Treatment of Atopic Dermatitis
Tickers: REGN, SNY
Occurred on: Mar 28, 2017 -
Sanofi (SNY) and Regeneron (REGN) Announce U.S Lawsuit Against Amgen (AMGN) Over Patent for Asthma Drug
Tickers: AMGN, REGN, SNY
Occurred on: Mar 21, 2017 -
Regeneron (REGN) and Sanofi's (SNY) Sarilumab Approved in Canada for Adult Patients with Moderately to Severely Active Rheumatoid Arthritis (RA)
Tickers: SNY, REGN
Occurred on: Feb 01, 2017 -
Delaware District Court Denies Sanofi (SNY) and Regeneron's (REGN) Motion to Stay the Injunction in PCSK9 Patent Dispute with Amgen (AMGN)
Tickers: REGN, AMGN, SNY
Occurred on: Jan 09, 2017 -
Regeneron (REGN) and Sanofi (SNY) to Present Data from Phase 3 Praluent (alirocumab) Injection Clinical Trials at AHA Scientific Sessions 2016
Tickers: REGN, SNY
Occurred on: Nov 12, 2016 -
FDA accepts sarilumab BLA; PDUFA date October 30
Ticker: REGN
Occurred on: Oct 28, 2016 -
Regeneron (REGN) and Sanofi's (SNY) Sarilumab for Rheumatoid Arthritis Granted PDUFA date of October 30, 2016 by FDA
Tickers: REGN, JNJ, SNY, GSK
Occurred on: Oct 28, 2016 -
FDA Places Hold on Teva (TEVA) and Regeneron's (REGN) Phase 2b Trial Evaluating Fasinumab in Chronic Low Back Pain
Tickers: TEVA, REGN
Occurred on: Oct 17, 2016 -
Regeneron (REGN) and Sanofi's (SNY) Biologics License Application for Dupilumab in Atopic Dermatitis (AD) Accepted for Priority Review by FDA
Tickers: REGN, SNY
Occurred on: Sep 26, 2016 -
GlaxoSmithKline (GSK) and Johnson & Johnson (JNJ) Plan to Submit Application to FDA in 2016 for Sirukumab in Rheumatoid Arthritis
Tickers: GSK, REGN, SNY, JNJ
Occurred on: Sep 23, 2016 -
GlaxoSmithKline (GSK) and Johnson & Johnson (JNJ) Submit Sirukumab in Treatment of Rheumatoid Arthritis to European Medicines Agency
Tickers: GSK, JNJ, SNY, REGN
Occurred on: Sep 12, 2016 -
Regeneron Announces Agreement with BARDA for the Manufacturing and Testing of New Antibodies Against MERS Virus
Ticker: REGN
Occurred on: Aug 22, 2016 -
CymaBay (CBAY) to Present Two Phase 2 Studies of Arhalofenate for Gout Patients at the American College of Rheumatology Annual Meeting
Tickers: CBAY, CELG, AZN, REGN
Occurred on: Nov 07, 2015
Strategic Initiatives (REGN)
-
Regeneron and Sanofi To Accelerate and Expand Investment for Cemiplimab and Dupilumab Development Programs
Tickers: REGN, SNY
Announcement Date: Jan 08, 2018 -
Ocular Therapeutics (OCUL) and Regeneron (REGN) Agree to Develop a Sustained-Release Formulation of Aflibercept for Wet Age-Related Macular Degeneration (Wet AMD)
Tickers: OCUL, REGN
Announcement Date: Oct 13, 2016 -
Teva (TEVA) and Regeneron (REGN) Agree to Global Commercialization and Development Deal for REGN's Fasinumab in Chronic Lower Back Pain
Tickers: TEVA, REGN
Announcement Date: Sep 20, 2016
